根据该协议的条款，该集团同意授予阿斯利康在全球开发、制造及商业化该化合物及该产品的独家授权。该集团将收取1.0亿美元的预付款，并有权收取最高3.7亿美元的潜在开发里程碑付款及最高15.5亿美元的潜在销售里程碑付款，以及根据该产品的年度销售净额计算的分层销售提成。CSPC Pharma (01093) opened over 9%, as of the time of publication, rose by 9.55%, reported at 7.8 Hong Kong dollars, with a turnover of 0.114 billion Hong Kong dollars.
According to the Futu Securities app, CSPC Pharma (01093) opened over 9%, rose by 9.55% as of the time of publication, reported at 7.8 Hong Kong dollars, with a turnover of 0.114 billion Hong Kong dollars.
On the news front, CSPC Pharma announced that the group has entered into an exclusive authorization agreement with Astrazeneca to develop, manufacture, and commercialize the group's lipoprotein(a) inhibitor YS2302018 globally, as well as any drugs or biological products containing or composed of this compound in the future.
Under the terms of the agreement, the group has agreed to grant Astrazeneca the exclusive authorization to develop, manufacture, and commercialize this compound and product globally. The group will receive a prepayment of 0.1 billion US dollars and is entitled to receive up to 0.37 billion US dollars in potential development milestone payments and up to 1.55 billion US dollars in potential sales milestone payments, as well as tiered sales royalties based on the annual net sales of the product.
As a leading preclinical candidate drug, this compound was discovered by the group's AI-driven small molecule drug design platform. This platform utilizes AI technology to analyze the binding modes of target proteins with existing compound molecules, selectively optimize their drug-like properties, and ultimately screen out highly efficient and developmentally excellent small molecule inhibitors of Lp(a). This compound has shown effectiveness in binding to apolipoprotein(a) (Apo(a)), thereby preventing it from assembling with ApoB-100 particles to form Lp(a).
